Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants

Blood (2021) 137 (14): 1980–1984.

https://doi.org/10.1182/blood.2020009032

Published: 2021

Includes: Supplemental data

Journal Articles

Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort

Laura Rachele Bettini, Claudia Saitta, Barbara Buldini, Geertruij Te Kronnie, Stefano Rebellato, Daniela Silvestri, Elena Barisone, Andrea Pession, Marco Rabusin, Concetta Micalizzi, Franco Locatelli, MD PhD, Carmelo Rizzari, Maria Grazia Valsecchi, PhD, Andrea Biondi, MD, Grazia Fazio, Giovanni Cazzaniga, PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-142729

Published: 2020

Journal Articles

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Blood (2016) 127 (17): 2101–2112.

https://doi.org/10.1182/blood-2015-09-670729

Published: 2016

Includes: Supplemental data

Journal Articles

Clonal Evolution and Lack of BCR-ABL1 Mutations in Pediatric Ph+ ALL Patients Resistant/Refractory to Imatinib Treatment

Valeria Cazzaniga, PhD, Paola De Lorenzo, Federica Mottadelli, Grazia Fazio, PhD, Tiziana Villa, Vincenzo Rossi, Martina Pigazzi, PhD, Marcela B. Mansur, PhD, Marco Zecca, MD, Elena Barisone, MD, Franco Locatelli, MD, Giuseppe Basso, Prof, MD, Maria Grazia Valsecchi, PhD, Mel Greaves, FRS, Andrea Biondi, Prof, MD, Anthony M Ford, Giovanni Cazzaniga

Blood (2015) 126 (23): 2622.

https://doi.org/10.1182/blood.V126.23.2622.2622

Published: 2015

Journal Articles

CRLF2 over-Expression Is a Poor Prognostic Marker in Children with High Risk T-Cell Acute Lymphoblastic Leukemia

Blood (2014) 124 (21): 1071.

https://doi.org/10.1182/blood.V124.21.1071.1071

Published: 2014

Journal Articles

FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia

Nellina Andriano, Barbara Buldini, Daniela Silvestri, Tiziana Villa, Franco Locatelli, Rosanna Parasole, Elena Barisone, Anna Maria Testi, Andrea Biondi, Maria Grazia Valsecchi, Valentino Conter, Giuseppe Basso, Luca Lo Nigro, Giovanni Cazzaniga

Blood (2014) 124 (21): 1073.

https://doi.org/10.1182/blood.V124.21.1073.1073

Published: 2014

Journal Articles

Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study

Blood (2014) 124 (21): 3780.

https://doi.org/10.1182/blood.V124.21.3780.3780

Published: 2014

Journal Articles

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

Blood (2014) 123 (10): 1470–1478.

https://doi.org/10.1182/blood-2013-10-532598

Published: 2014

Includes: Supplemental data

Journal Articles

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Blood (2010) 115 (16): 3206–3214.

https://doi.org/10.1182/blood-2009-10-248146

Published: 2010

Includes: Supplemental data

Journal Articles

Detection of CALM-AF10 Fusion Transcript Does Not Predict A Poor Prognosis in Children with T-Lineage Acute Lymphoblastic Leukemia Treated with AIEOP ALL 2000 Protocol and Subsequent Modified 2000 Study (R-2006).

Blood (2009) 114 (22): 1578.

https://doi.org/10.1182/blood.V114.22.1578.1578

Published: 2009

Journal Articles

Results of the AIEOP-BFM ALL 2000 Study for Childhood Acute Lymphoblastic Leukemia IN AIEOP High Risk Patients.

Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Maurizio Aricò, Carmelo Rizzari, Rosanna Parasole, Chiara Messina, Giulio De Rossi, Elena Barisone, Luca Lo Nigro, Nicola Santoro, Ottavio Ziino, Franco Locatelli, Andrea Pession, Anna Maria Testi, Concetta Micalizzi, Andrea Biondi, Giuseppe Basso, Daniela Silvestri, Giuseppe Masera, MD

Blood (2009) 114 (22): 319.

https://doi.org/10.1182/blood.V114.22.319.319

Published: 2009

Journal Articles

Relapse in Childhood “Very High Risk” Acute Lymphoblastic Leukemia Treated with BFM Chemotherapy Has a Dismal Outcome Even When Treated with Transplantation.

Adriana Balduzzi, MD, Maria Grazia Valsecchi, PhD, André Schrauder, MD, Daniela Silvestri, MSc, Barbara Buldini, MD, Arend von Stackelberg, MD, Anna Maria Testi, MD, Thomas Klingebiel, MD, Christina Peters, MD, Carmelo Rizzari, MD, Elena Barisone, MD, Martin Schrappe, MD

Blood (2008) 112 (11): 915.

https://doi.org/10.1182/blood.V112.11.915.915

Published: 2008

Journal Articles

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Blood (2007) 110 (11): 1425.

https://doi.org/10.1182/blood.V110.11.1425.1425

Published: 2007

Journal Articles

Long Term Results of the AIEOP-All-95 Trial for Childhood Acute Lymphoblastic Leukemia. An Insight on the Prognostic Value of Dna Index in the Frame of BFM-Based Chemotherapy.

Maurizio Arico, Maria Grazia Valsecchi, Carmelo Rizzari, Elena Barisone, Andrea Biondi, Fiorina Casale, Franco Locatelli, Luca Lo Nigro, Matteo Luciani, Chiara Messina, Concetta Micalizzi, Rosanna Parasole, Andrea Pession, Nicola Santoro, Anna Maria Testi, Daniela Silvestri, Giuseppe Basso, Giuseppe Masera, Valentino Conter

Blood (2007) 110 (11): 1440.

https://doi.org/10.1182/blood.V110.11.1440.1440

Published: 2007

Journal Articles

TEL/AML1 Rearrangement Is Rare in Children with Acute Lymphoblastic Leukemia (ALL) and Down Syndrome (DS). Presenting Features and Treatment Outcome in the Experience of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).

Blood (2007) 110 (11): 848.

https://doi.org/10.1182/blood.V110.11.848.848

Published: 2007

Journal Articles

High Dose Methotrexate (HD MTX at 2 gr/sqm x 4) Associated to Extended Intrathecal (IT) Chemotherapy Is Effective for Prevention of Central Nervous System (CNS) Relapse in Childhood ALL Treated with BFM Systemic Therapy.

Blood (2005) 106 (11): 10.

https://doi.org/10.1182/blood.V106.11.10.10

Published: 2005

Journal Articles

Children with TEL/AML1-Positive Acute Lymphoblastic Leukemia (ALL) and Favorable Presenting Features May Benefit from the Use of Vincristine-Dexamethasone (VCR-DXM) Pulses on Top of Antimetabolite-Based Continuation Therapy.

Blood (2005) 106 (11): 9.

https://doi.org/10.1182/blood.V106.11.9.9

Published: 2005

Journal Articles

Acute Lymphoblastic Leukemia in Children with Associated Genetic Conditions Other Than Down Syndrome. The AIEOP Experience.

Ottavio Ziino, Roberto Rondelli, Fulvio Porta, Rossella Mura, Concetta Micalizzi, Valentino Conter, Marie France Pinta Boccalatte, Chiara Messina, Matteo Luciani, Elena Barisone, Franco Locatelli, Andrea Pession, Giuseppe Basso, Andrea Biondi, Giuseppe Masera, Maurizio Aricò

Blood (2005) 106 (11): 863.

https://doi.org/10.1182/blood.V106.11.863.863

Published: 2005

Journal Articles

GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children

Anna Maria Testi, Andrea Biondi, Francesco Lo Coco, Maria Luisa Moleti, Fiorina Giona, Marco Vignetti, Giuseppe Menna, Franco Locatelli, Andrea Pession, Elena Barisone, Giulio De Rossi, Daniela Diverio, Concetta Micalizzi, Maurizio Aricò, Giuseppe Basso, Robert Foa, Franco Mandelli

Blood (2005) 106 (2): 447–453.

https://doi.org/10.1182/blood-2004-05-1971

Published: 2005

Journal Articles

Three-Drug Induction and BFM-Type Intensive Consolidation Chemotherapy for Treatment of Standard Risk Childhood Acute Lymphoblastic Leukemia Defined Also by DNA index. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Study ALL-9501.

Maurizio Arico’, Valentino Conter, Maria Grazia Valsecchi, Marie France Pinta Boccalatte, Elena Barisone, Chiara Messina, Giulio De Rossi, Luca Lo Nigro, Andrea Pession, Franco Locatelli, Concetta Micalizzi, Giuseppe Basso, Giuseppe Masera

Blood (2004) 104 (11): 1951.

https://doi.org/10.1182/blood.V104.11.1951.1951

Published: 2004

NARROW

Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants

Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Clonal Evolution and Lack of BCR-ABL1 Mutations in Pediatric Ph+ ALL Patients Resistant/Refractory to Imatinib Treatment

CRLF2 over-Expression Is a Poor Prognostic Marker in Children with High Risk T-Cell Acute Lymphoblastic Leukemia

FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia

Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Detection of CALM-AF10 Fusion Transcript Does Not Predict A Poor Prognosis in Children with T-Lineage Acute Lymphoblastic Leukemia Treated with AIEOP ALL 2000 Protocol and Subsequent Modified 2000 Study (R-2006).

Results of the AIEOP-BFM ALL 2000 Study for Childhood Acute Lymphoblastic Leukemia IN AIEOP High Risk Patients.

Relapse in Childhood “Very High Risk” Acute Lymphoblastic Leukemia Treated with BFM Chemotherapy Has a Dismal Outcome Even When Treated with Transplantation.

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Long Term Results of the AIEOP-All-95 Trial for Childhood Acute Lymphoblastic Leukemia. An Insight on the Prognostic Value of Dna Index in the Frame of BFM-Based Chemotherapy.

TEL/AML1 Rearrangement Is Rare in Children with Acute Lymphoblastic Leukemia (ALL) and Down Syndrome (DS). Presenting Features and Treatment Outcome in the Experience of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).

High Dose Methotrexate (HD MTX at 2 gr/sqm x 4) Associated to Extended Intrathecal (IT) Chemotherapy Is Effective for Prevention of Central Nervous System (CNS) Relapse in Childhood ALL Treated with BFM Systemic Therapy.

Children with TEL/AML1-Positive Acute Lymphoblastic Leukemia (ALL) and Favorable Presenting Features May Benefit from the Use of Vincristine-Dexamethasone (VCR-DXM) Pulses on Top of Antimetabolite-Based Continuation Therapy.

Acute Lymphoblastic Leukemia in Children with Associated Genetic Conditions Other Than Down Syndrome. The AIEOP Experience.

GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children

Three-Drug Induction and BFM-Type Intensive Consolidation Chemotherapy for Treatment of Standard Risk Childhood Acute Lymphoblastic Leukemia Defined Also by DNA index. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Study ALL-9501.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only